Study On FCGBP As A Potential Immune-related Prognostic Marker And Target Of Glioma

Objective:Immune microenvironment serves a vital role in glioma progression,and numerous studies have found that tumor progression can be reduced to some extent by modulating the immune process in tumors.Methods:Immune Score of each sample in CGGA datasets were calculated with Estimate R package,and samples were grouped by median Immune Score values for differential analysis to obtain immune microenvironment differential genes.The survival analysis of glioma sample genes in CGGA was carried out to screen the prognostic genes.After ROC curve analysis,independent prognostic analysis and clinical correlation analysis,the prognostic genes of glioma were obtained,and then the intersection genes between them and immune microenvironment difference genes were determined by Venn tool.GEPIA and UALCAN databases were used to confirm the differential expression again and identify our target genes.After validation of their prognostic value,we constructed a nomogram to calculate the risk score and to estimate the accuracy of prognostic model.We mined co-expression genes,enriched functions and pathways,and correlations to immune cell infiltration of unigene with an online database.Finally,we verified the differential expression of FCGBP in glioma by immunohistochemical staining.Results:We finally selected Fc fragment of Ig G-binding protein(FCGBP)as our targrt gene.The prognostic values of FCGBP were validated by a series of analyses.Immunohistochemical staining showed that FCGBP expression increased in gliomas and was up-regulated with the progression of glioma grade.Conclusion:1.FCGBP is up-regulated in glioma.It is an independent prognostic risk factor and can be used as a potential prognostic marker for glioma.2.The up-regulated level of FCGBP expression is related to the WHO grade,primary-recurrent-recurrent status,histological classification,immune cell infiltration,IDH mutation and 1p19 q co-deletion of glioma,which plays a certain role in regulating the immune microenvironment of glioma and is a potential immunotherapy target.